ArticleFrontiers in immunology2025
Identification of necroptosis-associated mRNA biomarkers in kidney clear cell carcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognosis Comparison Between Synchronous and Metachronous Metastasis of Renal Cell Carcinoma: A Meta-Analysis and Systematic Review.Annals of surgical oncology · 2026Review
- Integrative analysis identifies a glycosylation-related lncRNA signature associated with prognosis in kidney renal clear cell carcinoma.Translational andrology and urology · 2026Article
- Unveiling the novel role of PGAM5 in rewiring metabolism through PI3K/AKT/mTOR signaling in acute myelogenous leukemia.Scientific reports · 2026Article
- Integrating machine learning, deep learning, and docking to predict aristolochic acid A carcinogenesis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Kidney clear cell carcinoma (KIRC) is the most common subtype of renal malignancy with a high mortality rate. It is difficult to treat and often leads to death due to its genomic heterogeneity, metastatic nature, and limited effectiveness of targeted and immunotherapies. Recent studies showed that the progression of KIRC is frequently accompanied by significant changes in necroptosis while these studies were limited by small gene sets, which increases the risk of missing low-expressed yet important genes. Methods: This study focused on necroptosis-associated genes within the context of KIRC and performed a complete closed-loop studies by gene screening, gene expression analysis, model validation and experimental translation. Results: Among screened nine core biomarkers ( Conclusion: This study offers multi-dimensional data that support novel mechanistic investigations and provide valuable insights for developing precision immunotherapy strategies in KIRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.